Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
Netherlands Antilles
(0/week)
View all
(0/week)
News
United States
(727/week)
Manufacturing
(378/week)
Energy
(313/week)
Technology
(699/week)
Other Manufacturing
(245/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Conjunctivitis
May 07, 2020
World Market for Allergy Relieving Eye Drops: Forecasts and Coverage of Key Players Including Allergan, Pfizer and Regeneron Pharmaceuticals
Mar 30, 2020
Eyevance Pharmaceuticals Launches ZERVIATE(TM) in the United States
Dec 20, 2019
iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis
May 08, 2019
The Relief Products(TM) Introduces New PM Ointments to Support Nighttime Healing and Recuperative Sleep
Mar 26, 2019
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Mar 26, 2019
Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results
Mar 25, 2019
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
Feb 25, 2019
Allergy relieving Eye Drops Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Jan 31, 2019
Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis
Dec 20, 2018
Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial
Dec 04, 2018
Juntendo University Research: Omega-3 Fatty Acids Suppress Allergic Conjunctivitis Symptoms
May 15, 2018
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
May 07, 2018
Sylentis Announces New Data on the Treatment of Allergic Conjunctivitis
Apr 24, 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Mar 29, 2018
Aldeyra Therapeutics Announces Year End 2017 Financial Results
Feb 21, 2018
Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Dec 12, 2017
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis
Nov 09, 2017
Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
Oct 10, 2017
Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day
Aug 08, 2017
Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results
Latest News
Jul 8, 2025
Mitsubishi Electric Named to CDP Supplier Engagement Assessment Leaderboard
Jul 8, 2025
Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success
Jul 8, 2025
Liberty Energy Inc. Announces Date Change for its Second Quarter 2025 Earnings Release and Conference Call
Jul 8, 2025
Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G...
Jul 8, 2025
Faraday Future Announces the Launch of the Early Reservation Portal for Faraday X (FX) Official FX Super One...
Jul 8, 2025
Luxfer Declares Quarterly Dividend
Jul 8, 2025
IDEX Corporation to Webcast Second Quarter 2025 Earnings Call
Jul 8, 2025
Avolon Announces Pricing of US$650 Million Senior Unsecured Notes Offering
View all News
Agenda
30
September
Portugal
Troia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United Kingdom
London, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events